<DOC>
	<DOCNO>NCT02486952</DOCNO>
	<brief_summary>Evaluation efficacy , safety profile tolerability rituximab ( MabThera ) combination chemotherapy treatment Diffuse Large B-Cell Lymphoma ( DLBCL ) . Participants , treat previously DLBCL , receive MabThera combination Cyclophosphamide , Hydroxydaunorubicin , Oncovin , Prednisone ( CHOP ) CHOP-like chemotherapy accord registered indication . Patients follow safety efficacy evaluation accordance routine practice . The study non-interventional design purely observational . All treatment prescribe observation period treat physician 's discretion prescribe accord package labeling , within approve indication local approval status respective drug .</brief_summary>
	<brief_title>MabThera ( Rituximab ) Combination With CHOP ( CHOP-like ) Chemotherapy Patients With Aggressive B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm cluster differentiation antigen 20 ( CD20 ) positive Diffuse Large BCell Lymphoma accord World Health Organization/Revised EuropeanAmerican Classification Lymphoid Neoplasms ( WHO/REAL ) classification Age &gt; =18 year Performance status &lt; = 2 Eastern Cooperative Oncology Group ( ECOG ) scale Women childbearing potential must agree use effective contraception entire treatment period 12 month thereafter Transformed lymphoma ( secondary `` lowgrade '' follicular lymphoma ) Grade 1 , 2 3a follicular lymphoma Primary secondary central nervous system ( CNS ) involvement Patients prior concomitant malignancy except nonmelanoma skin cancer adequately treat situ cervical cancer Major surgery ( exclude lymph node biopsy ) within 28 day prior registration . Poor renal function : Serum creatinine &gt; 2.0 mg/dl ( 177 micromol/L ) Pregnancy Poor hepatic function : total bilirubin &gt; 2.0 mg/dl ( 34 micromol/L ) , aspartate transaminase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine transaminase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) alkaline phosphatase ( AP ) &gt; 3 x upper limit normal unless abnormality relate lymphoma . Known human immunodeficiency virus ( HIV ) infection active viral hepatitis , specifically hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Serious underlie medical condition , could impair ability patient participate trial Life expectancy &lt; 6 month Known sensitivity allergy murine product Treatment within clinical trial within 30 day prior trial entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>